The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | Severe COVID-19 in patients with hematological malignancies
Samuel Rubinstein, MD, University of North Carolina, Chapel Hill, NC, discusses the findings of a study by the COVID-19 and Cancer Consortium (CCC19; NCT04354701) investigating the clinical course and complications of COVID-19 in patients with cancer. 757 patients with hematological malignancies and COVID-19 were enrolled in the study. The study found that the rate of severe COVID-19 infection was highest in patients with chronic lymphocytic leukemia (53%) and lowest in patients with Hodgkin lymphoma (23%). Patients who had received cytotoxic systemic therapy within three months of COVID-19 diagnosis had higher rates of severe COVID-19 infection than those who had received treatment longer ago. There was no significant difference in the rates of severe COVID-19 infection when comparing patients who had received cellular or transplant therapy within a year prior to infection versus those who had not, or when comparing patients receiving first-line therapy versus second-line or later therapy. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
